The success rate of the ABVD regimen is generally high, especially for early-stage Hodgkin Lymphoma. Studies have shown that the 5-year survival rate for patients treated with ABVD can exceed 80%, particularly when diagnosed early. However, the success rate can vary based on a number of factors, including the stage of the cancer and the patient’s overall health.
